• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    缅因州医疗中心

    缅因州医疗中心

    Maine Medical Center
    EST. 1874
    1,730论文总数
    6.8万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1730)

    年份
    起
    –
    止
    排序
    1American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes - 2026 Update.
    Susan L Samson,Priyathama Vellanki,Lawrence Blonde, Irl B Hirsch,Thanh D Hoang, Scott D Isaacs, Kenneth E Izuora,Cecilia C Low Wang, Cheow Peng Ooi,Blanca Iris Padilla, Rifka Schulman-Rosenbaum, Christine L Twining,

    OBJECTIVE:This consensus statement provides evidence-based visual guidance in graphic algorithms and a summary of evidence and considerations to assist health care professionals with the diagnosis and management of adults with prediabetes and diabetes mellitus in shared decision making to improve care. METHODS:The American Association of Clinical Endocrinology (AACE) selected a task force of medical experts to update the 2023 AACE Comprehensive Type 2 Diabetes Management Algorithm and align this algorithm update with related AACE clinical guidance. RESULTS:This algorithm for management of adults with type 2 diabetes (T2D) includes 11 sections: (1) Principles for the Management of Adults With T2D; (2) Prediabetes Algorithm (3) Diabetes Classification Algorithm (new); (4) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia; (5) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Hypertension; (6) Comorbidities- and Complications-Centric Glycemic Control Algorithm; (7) Glucose-Centric Glycemic Control Algorithm; (8) Initiating and Titrating Insulin Algorithm; (9) Profiles of Pharmacotherapy for T2D; (10) Profiles of Pharmacotherapy for Obesity; and (11) Vaccine Recommendations for Adults With T2D. CONCLUSIONS:This 2026 update emphasizes lifestyle modification and treatment of overweight/obesity as key pillars in the management of prediabetes and T2D. It also provides guidance on the management of atherosclerotic risk factors of dyslipidemia and hypertension. A new algorithm was added to ensure that other causes and classes of diabetes are considered beyond T2D. There continues to be an emphasis on a complications- and comorbidities-centric approach, beyond glucose levels, to frame decisions regarding first-line and subsequent pharmacological choices for treating adults with T2D.

    2026Endocrine practice official journal of the American College of Endocrinology and the American Assoc...(2026)引用:4
    引用
    AI阅读
    加入学术空间
    2The Optimizing Whiteboard Lectures (OWL) Checklist: Validation of a Novel "chalk Talk" Assessment Tool.
    Ryan E. Nelson,Jason A. Freed, Tianyu Sissi Chen, Monica Thim, Sarah Olofsson,Stephen R. Pelletier, Daniel N. Ricotta

    Internal medicine (IM) trainees routinely use whiteboard mini-lectures (WMLs) to teach in clinical settings. Despite their widespread use, there is no standardized, evidence-based assessment tool to evaluate WML quality and structure formative feedback. To develop and collect validity evidence for the Optimizing Whiteboard Lectures (OWL) Checklist, a novel WML assessment tool, using Kane’s four-stage model Prospective, multi-center observational study. Fifty-one IM residents, fellows, and CMRs delivered 56 WMLs. Twenty-four raters (attendings, fellows, and chief medical residents (CMRs)) performed a total of 91 (43 individual and 48 paired or multi-rater) WML observations. The OWL Checklist comprises 20 dichotomous behavioral items and a global measure of teaching performance for a maximum score of 24. We collated validity evidence across Kane’s four inferences: (1) scoring, through instrument development, rater training, and rater perception surveys; (2) generalization, via inter-rater reliability; (3) extrapolation, by stratifying scores across post-graduate year (PGY) level and by rater perception surveys; and (4) implications, via teacher perception surveys. We found strong reliability among raters (κ = 0.86) and a significant upward trend in OWL Checklist scores from PGY-1 to CMRs (p = 0.004). Nineteen raters (79

    2026Journal of General Internal Medicine(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival among People with Non-Small Cell Lung Cancer
    Jingxuan Zhao,Ilana Graetz,David Howard,Xuesong Han,Lu Zhang, Xiao Hu, K Robin Yabroff,Joseph Lipscomb

    Purpose: To examine the associations between Medicaid expansion and stage at diagnosis, timely initiation and receipt of guideline-concordant treatment, and 5-year overall survival (OS) among people with non-small cell lung cancer (NSCLC). Methods: Individuals newly diagnosed with stage I to IV NSCLC at age 18-64 years between January 1, 2004, and December 31, 2023, in 50 states and Washington, DC, were identified from the National Cancer Database. We examined the association of Medicaid expansion and (1) early-stage diagnosis (I and II); (2) timely initiation of guideline-concordant treatment within 30 days after diagnosis; (3) receipt of all first-course guideline-concordant treatment; and (4) 5-year OS. We applied conventional and updated (Sun and Abraham) difference-in-differences (DID) approaches to examine the changes in study outcomes associated with Medicaid expansion using multivariable linear probability models to estimate stage and treatment and multivariable flexible parametric survival models to investigate survival overall and by key factors. Results: Compared with people in nonexpansion states (n = 164,228), people in expansion states (n = 350,290) were more likely to be female, non-Hispanic White, or living in areas with higher family income or in nonmetropolitan areas. Medicaid expansion was associated with increases in early-stage NSCLC diagnosis (DID: 1.02 percentage points [ppt; 95% CI, 0.52 to 1.52]), timely treatment initiation (2.10 ppt [95% CI, 0.05 to 4.15]), and higher 5-year OS (1.79 ppt [95% CI, 1.32 to 2.26]). In stratified analyses, people living in areas with lower household income were more likely to benefit from Medicaid expansion. Conclusion: Medicaid expansion was associated with improvements in early detection, timeliness of guideline-concordant treatment, and survival for people with NSCLC. Anticipated Medicaid coverage losses may jeopardize these gains.

    2026Journal of clinical oncology official journal of the American Society of Clinical Oncology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4AO Spine Clinical Practice Recommendations for Adjunctive Medical Therapies in Acute Traumatic Spinal Cord Injury: Contemporary Concepts
    Chris J Neal, Ricardo Rodrigues-Pinto,Lukas Grassner,Vanessa Hubertus, Farzin Farahbakhsh, Jetan H Badhiwala,David B Anderson,Nader Hejrati,Paul Arnold,Michael G Fehlings,Brian K Kwon, Charles G Fisher,

    Study Design Review of the literature with critical appraisal and clinical recommendations.Objective To highlight contemporary concepts involving adjunctive medical and non-surgical therapies in the management of acute traumatic spinal cord injury (tSCI) that may be integrated into clinical practice.Methods Three recent articles relating to the management of acute tSCI were selected and critically appraised. Clinical practice recommendations were developed and evaluated using the GRADE criteria.Results Article 1: A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on Hemodynamic Management. Conditional recommendation to augment mean arterial blood pressure to at least 75-80 mmHg but not higher than 90-95 mmHg for a duration of 3-7 days to optimize spinal cord perfusion in acute tSCI. Article 2: Spinal Cord Perfusion Pressure Predicts Neurologic Recovery in Acute Spinal Cord Injury. No recommendation can be made at this time in the utilization of SCPP-guided hemodynamic management as an adjunctive strategy in the acute care of tSCI. Article 3: Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS). No recommendation can currently be made on the routine use of riluzole to patients with acute cervical tSCI.Conclusions The management of tSCI extends beyond the operating room. The development of emerging medical and non-surgical treatments to augment timely and adequate decompression requires critical consideration as new data becomes available. While some topics do not have the scientific backing to be able to make a recommendation at this time, they point towards areas of future study.

    2026Global spine journal(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Platelet FcɣRIIa Expression Refines Clinical Risk Assessment after Myocardial Infarction
    David J Schneider,Sean R McMahon, Dominick J Angiolillo, Alexander C Fanaroff,Homam Ibrahim, Patrick K Hohl, Brett L Wanamaker, Mark B Effron,Peter M DiBattiste, Behalf Of The Investigators

    BACKGROUND:In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. AIMS:Assess the prognostic implications of clinical risk alone and in combination with the pFCG test. METHODS:Patients (n = 749) were enrolled in a prospective non-interventional trial during hospitalization with type 1 MI (ST elevation and non-ST elevation). Inclusion criteria included ≥ 2 of the following clinical risk factors: age ≥ 65, multi-vessel coronary artery disease, prior MI, chronic kidney disease, or diabetes mellitus. High and low pFCG (quantified by flow cytometry at a core laboratory) were defined by a prespecified threshold. The primary endpoint was the composite of MI, stroke, and death. RESULTS:Distribution of clinical risk factors was 346 patients (45%) with 2 factors, 272 patients (36%) with 3 factors, and 131 patients (17%) with 4 or 5 factors. A greater number of risk factors was associated with a greater risk of the composite of MI, stroke, and death after 1 year. The event rate with 2 risk factors was 10.2%, with 3 factors it was 14.4%, and with 4/5 factors it was 35.6%. Across all cohorts of clinical risk, the pFCG test identified a higher-risk and a lower-risk cohort. CONCLUSIONS:Both clinical risk and the pFCG test assess prognosis. Results of the pFCG test refine the prognosis defined by clinical risk. The prognostic implications suggest that the pFCG test may be a useful tool to balance ischemic risk with that of bleeding to define treatment strategy. CLINICAL TRIAL REGISTRATION:https://clinicaltrials.gov/study/NCT05175261.

    2026Catheterization and cardiovascular interventions official journal of the Society for Cardiac Angiog...(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1730 篇论文

    合作机构(100)

    塔夫茨大学合作论文 54
    华盛顿大学合作论文 38
    达特茅斯 - 希区柯克医学中心合作论文 36
    哈佛医学院合作论文 36
    Massachusetts General Hospital,Harvard Medical School合作论文 35
    密歇根大学合作论文 33
    加州大学合作论文 31
    缅因大学合作论文 29
    哈佛大学合作论文 29
    耶鲁大学合作论文 28

    机构统计